Thinly traded micro cap Gritstone Oncology (NASDAQ:GRTS) slumps 32% premarket on increased volume on the heels of its presentation of interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen therapeutic vaccine candidates, respectively, in patients with solid tumors.
Investors appear to have expected more significant treatment effects.
Phase 2 studies are next up.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.